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Introduction
Surgical resection according to the principles of total mesorectal excision (TME) is the mainstay of treatment for localised primary rectal cancer 1 . Routine adoption of TME and quality control of the resection specimens have led to a significant reduction of local recurrences and improvement of survival [1, 2] . Pre-operative short-course radiotherapy or long-course chemoradiotherapy have further improved complete excision and local recurrence rates but the impact of these treatments on long-term outcome of patients with resectable tumours is controversial [3, 4] .
Over the last decade, the term locally advanced rectal cancer (LARC) has been increasingly used mostly as a result of the continuous efforts to implement risk-adapted treatment strategies. While there has not been consensus on the exact definition of LARC, it is clear that this entity includes a spectrum of heterogeneous cancers at one end of which are tumours that require extensive surgical approaches (i.e., beyond the TME planes or exenterative-type procedures) to achieve clear margins and unresectable tumours [5, 6] . Residual cancer within a distance of ≤1 mm from the circumferential resection margin (CRM) and involvement of adjacent organs (i.e., T4b) have been reported in approximately 1-33% and 10% of rectal cancers patients, respectively [7, 8] . These high-risk tumours can be reliably identified at baseline by high-resolution magnetic resonance imaging (MRI) [9] and patients are routinely treated with long-course chemoradiotherapy with the aim to not only reduce the risk of local recurrence but also downstage/downsize the tumour and allow a standard TME procedure with >1 mm clearance of tumour to the radial margins.
It has been reported, however, that among patients with tumour involvement of the mesorectal fascia at baseline, 20% and 8% still have a predicted (i.e., imaging-based) CRM involvement and a positive pathological CRM after chemoradiotherapy, respectively [10] . Similarly, among patients who undergo chemoradiotherapy for tumours that are unresectable at diagnosis, 8% will remain inoperable and 28% will require an exenterative-type resection [11] . Poor response to chemoradiotherapy in these patients may have important clinical implications. A positive CRM is unanimously considered as one of the most powerful prognostic factors in rectal cancer due to its association with increased risk of both local and distant recurrence, and poor survival especially after administration of pre-operative radiotherapy [8] . Also, while exenterative-type surgical procedures can still achieve clear margins and compensate for inadequate tumour downstaging/downsizing after neoadjuvant therapy, these are likely burdened with higher rates of post-operative morbidity and mortality as well as deterioration of quality of life compared with standard TME [12, 13] . If, despite such extensive surgery, these patients succumb to distant metastatic disease (that now largely exceeds local recurrence as the main cause of death from rectal cancer) then the negative impact on quality of life may not be justified.
Current international guidelines suggest that radiotherapy dose escalation (i.e., additional 10-20 Gy beyond conventional dose), intraoperative radiotherapy (IORT) or brachytherapy could be considered for patients with close/positive margins, T4 or unresectable tumours after standard neoadjuvant therapy [14] . However, data to support these approaches are scarce and there is uncertainty regarding their efficacy [15] [16] [17] [18] . Notably, although mechanisms of radio-and chemoresistance may differ and full dose systemic chemotherapy may provide a non-cross resistant treatment to deliver after failure of chemoradiotherapy, the use of this strategy in this setting has never been investigated [19] .
In this article we report the results of a single institution, retrospective study that was designed to assess the impact of salvage systemic chemotherapy on the surgical approach and outcome of highrisk LARC patients who are still inoperable or candidates for extensive surgical procedures despite the use of standard long-course (chemo)radiotherapy.
Methods
All patients who were last seen in consultation at the Royal Marsden NHS Foundation Trust between April 2004 and July 2015 following a diagnosis of rectal cancer were reviewed and checked against the following study inclusion criteria: 1) histological confirmation of adenocarcinoma; 2) distal edge of the luminal tumour within 15 cm of the anal verge as assessed by baseline MRI; 3) newly diagnosed tumours (i.e., recurrent tumours excluded); 4) no evidence of distant metastases at diagnosis; 5) tumour deemed to be unresectable or requiring extensive surgery (i.e., beyond the TME planes) following completion of neoadjuvant long-course (chemo)radiotherapy and restaging MRI as per treating surgeon/multidisciplinary team (MDT) assessment; 6) systemic chemotherapy administered as salvage treatment after long-course (chemo)radiotherapy with the intent to enable an R0 resection within the TME planes; 7) full medical records available for data extraction.
According to the common practice at our institution over the study period, eligible patients underwent an MRI of the pelvis and a CT scan of the thorax, abdomen and pelvis at baseline for the purpose of tumour staging. The same scans were repeated after completion of neoadjuvant chemoradiotherapy and every 3 months during administration of salvage systemic chemotherapy.
At each time point, these were prospectively reviewed at weekly institutional MDT meetings (involving gastrointestinal radiologists, medical oncologists, radiation oncologists, colorectal surgeons, and pathologists) where tumour resectability was assessed and a recommendation was made regarding the next management plan. In particular, MRI reassessment included evaluation of tumour regression grade (mrTRG), depth of extramural spread for tumour/fibrosis and relationship in mm of tumour to the TME plane. For patients requiring exenterative surgery the MRI assessment also included documentation of the compartments/organs involved by tumour [20] . Data on demographics, clinico-pathological characteristics at baseline, neoadjuvant treatments, imaging at baseline, after (chemo)radiotherapy and after salvage systemic chemotherapy, pathology from resection specimens, adjuvant treatments, disease and survival status at the time of the analysis were retrospectively collected for each patient using the institutional electronic patient record system and entered into a database. Also, predicted type of surgery required based on imaging performed after completion of (chemo)radiotherapy and after systemic chemotherapy and type of surgery actually performed were annotated by reviewing the MDT recommendations (or surgical consultations if final decision was made at a later stage by the treating surgeon) and the operation notes, respectively. Pelvic MRI scans were retrospectively reviewed by a specialised gastrointestinal radiologist (GB) for the purpose of assessing some imaging parameters whenever corresponding data could not be extrapolated from the original radiology report.
The primary objective of the study was to assess the proportion of patients who were deemed to be unresectable or candidates for extensive surgery after (chemo)radiotherapy and became suitable (based on pre-operative imaging) for TME after salvage systemic chemotherapy. Secondary objectives included the proportion of patients who underwent TME surgery, rate of R0 resection, response to salvage systemic chemotherapy as assessed by imaging-based parameters [including T downstaging, N downstaging, 30% reduction of intraluminal cranio-caudal tumour length, change of extramural venous invasion (EMVI) status, change of CRM status, MRI tumour regression grade (mrTRG)], progression-free survival (PFS) and overall survival (OS) in the overall study population and in the curatively resected (i.e., R0 or R1 resection) population, and pattern of treatment failure.
T and N downstaging were defined as reduction of at least 1 level in T and N staging, respectively, between baseline MRI and post-treatment MRI or histopathological staging. mrTRG was defined as previously reported [21] . In brief, mrTRG 1 indicated radiological complete response (i.e., no evidence of residual tumour signal), mrTRG 2 good response (i.e., predominant fibrosis signal intensity with minimal residual tumor), mrTRG 3 moderate response (i.e., mixed areas of low signal fibrosis and intermediate signal intensity), mrTRG 4 minor response (i.e., persistent intermediate signal intensity with minimal low signal fibrosis) and mrTRG 5 no response (i.e., intermediate signal intensity, same appearances as original tumour). All survival outcomes were calculated from the start of salvage systemic chemotherapy. PFS was defined as time from start of systemic chemotherapy to date of progression (or unresectable disease based on either pre-operative imaging or intraoperative findings for those patients who did not undergo curative surgery) or death from any cause. OS was defined as time from start of systemic chemotherapy to date of death from any cause. Alive patients were censored at date of last follow-up. Both PFS and OS were analysed using the Kaplan-Meier method. Table 1 and 2, respectively. After MDT discussion and/or surgical consultation, 39 patients (86.7%) were deemed to be candidates for beyond TME surgery while 6 (13.3%) were considered inoperable (in 3 cases tumour unresectability was confirmed during explorative surgery).
Systemic treatment after (chemo)radiotherapy is presented in Table 3 . Doublet chemotherapy plus or minus bevacizumab was given to 44 patients (97.8%). In most cases patients received an oxaliplatin-based regimen (n=40, 88.9%) while an irinotecan-based regimen was used in 5 cases (11.1%, including one patients who started with single agent capecitabine and was subsequently switched to FOLFIRI). Treatment was administered for a median of 3. Table 1 and 2. Eight patients (17.8%) were diagnosed with distant metastases during or after completion of chemotherapy. Among the remaining 37 patients, the MDT and/or treating surgeon considered 29 (64.4%) as still either inoperable (including 1 patient who became unresectable due to local progression while on chemotherapy) or candidates for beyond TME surgery while 8 (17.8%) were deemed suitable for a TME approach. The latter group included 2 patients with unresectable tumours at baseline (as confirmed during explorative surgery) and 2 other patients who continued with the same chemotherapy despite the first MRI assessment after 3 months of treatment suggested that an extensive surgery would be still required (Figure 1 ). Median time from start of systemic chemotherapy to first MRI showing that a TME was technically feasible was 5.3 months (IQR: 3.5 -7.6; range: 3.0 -8.5).
A total of 23 patients (51.1%) underwent surgery with a curative intent (1 additional patient had an R2 palliative surgery which was required due to severe anal pain and MRI evidence of rectal perforation after chemotherapy). An extensive resection was undertaken in 13 cases while 10 patients were ultimately amenable to TME surgery (i.e., 5 anterior resections and 5 abdominoperineal resections) including 4 who were deemed to be candidates for a beyond TME surgery according to the MDT and/or treating surgeon (Figure 1 ). In these 4 cases, the interval between MRI after salvage chemotherapy and surgery was 30, 45, 87 and 91 days, respectively. An R0 resection (i.e., pathological CRM clear) was achieved in 21 cases, including all patients who underwent TME. A pathological complete response was observed in 3 patients (1 in the extensive surgery group and 2 in the TME group) ( Table 4 ). Reasons why surgery was not performed included: distant metastases (n=8), unresectable primary tumour (n=4, in 1 case tumour became unresectable due to local progression while awaiting patient decision regarding exenterative surgery), risk/benefit ratio of an exenterative procedure felt unacceptable by patient/physician (n=6), loss to follow-up (n=1). Two additional patients were proposed a "watch and wait" approach following radiological evidence of complete or almost complete tumour response. Post-operative adjuvant chemotherapy was administered in 7 patients (including 1 patient who also had cyberknife treatment due to a positive margin). The two patients who were managed with "watch and wait" were alive and free of disease after 19.7 and 24.6 months from start of salvage chemotherapy.
Discussion
In this study we have shown that administering systemic chemotherapy after poor response to neoadjuvant chemoradiotherapy may be an effective salvage strategy to allow a TME with clear surgical margins in some LARC patients who would otherwise be inoperable or candidates for an extensive surgery.
Over the last few years, an interest in the use of systemic chemotherapy in the pre-operative setting has increasingly emerged. A number of strategies have been investigated including induction chemotherapy before chemoradiotherapy [22] , systemic chemotherapy (without radiotherapy) followed by surgery [23] , and consolidation chemotherapy after chemoradiotherapy [24] , all with encouraging results. Nevertheless, to our knowledge, the potential of chemotherapy as a salvage treatment for patients who achieve suboptimal response to chemoradiotherapy has never been explored.
Our series included a selected group of poor-prognosis LARC patients as shown by the high proportion of tumours with prognostically unfavourable imaging characteristics at baseline (i.e., advanced TN stage, presence of EMVI and predicted CRM involvement) and the lack of substantial downstaging/regression after long-course (chemo)radiotherapy. More importantly, despite the use of standard neoadjuvant therapy, all patients were candidates for either an aggressive surgical approach (i.e., beyond the conventional TME planes) or a palliative treatment due to the local extent of their tumours. Further confirmation of the poor prognosis of our study population is provided by the modest long-term survival outcomes including a 3-year PFS of 30.0% and a 5-year OS of 42.8% which lag far behind the corresponding historical figures for unselected LARC patients who are treated with neoadjuvant chemoradiotherapy [25] .
The findings of our study suggest that 1 out of 5 such high-risk LARC patients can have their tumour resected or be spared from the consequences of an extensive surgery following the use of sequential systemic chemotherapy. Notably, all patients who underwent TME had negative surgical margin (i.e., R0 resection) and in two cases a pathological complete response was also observed.
Moreover, two additional patients had the opportunity to avoid surgery and undergo a "watch and wait" approach due to the radiologic evidence of a clinical complete response at the end of chemotherapy. Although the absence of an appropriate control group and the unavailability of patient reported outcome data do not allow us to draw any definitive conclusion, it is likely that the change of surgical approach resulting from the administration of salvage systemic chemotherapy might have minimised the risk of tumour-and treatment-related morbidities and translated into better quality of life and improved survival.
Delay of surgery and increased risk of tumour progression is one of the main concerns around the administration of chemotherapy in patients who are still amenable to an extensive resection after completion of standard chemoradiotherapy. In our study, however, local tumour progression precluding curative resection after salvage chemotherapy occurred only in 1 out of 39 potentially resectable patients (2.6%). Although a further 18% were diagnosed with distant metastases while on or soon after completion of chemotherapy, it is unlikely that these patients might have missed the chance of a potentially curative surgical resection. These patients are known to be at high risk of distant failure and lack of response to chemoradiotherapy is a further high-risk feature. Stretching the interval from chemoradiotherapy to surgery by administering sequential chemotherapy could actually provide an opportunity window to identify poor prognosis patients with rapidly progressing tumours and restrict exenterative-type surgical resections to those who are most likely to benefit.
While the overall impact of systemic chemotherapy in this setting may appear promising (i.e., change of treatment approach in 26.7% of cases) it is possible that there is scope for yet further improvement. Virtually all study patients were treated with oxaliplatin-or irinotecan-based doublet chemotherapy whereas only a minority (6.7%) also received bevacizumab. It is legitimate to hypothesise that more aggressive regimens including doublet chemotherapy plus either antiangiogenic agents or anti-EGFR monoclonal antibodies and triplet chemotherapy (plus or minus biologics) could lead to higher tumour regression rates and increase the proportion of patients who become candidates for a TME surgery despite poor response to chemoradiotherapy [26] [27] [28] [29] [30] . We have previously demonstrated that adding cetuximab to neoadjuvant doublet chemotherapy (i.e., before chemoradiotherapy) significantly improves the objective response rate in locally advanced rectal patients with RAS wild-type tumours [31, 32] . Furthermore, overexpression of EGFR has been reported to be a predictive factor of resistance to radiotherapy in rectal cancer and using anti-EGFR agents after failure of chemoradiotherapy may represent a rational strategy to target biologically aggressive tumour clones [33] [34] [35] [36] [37] .
While some patients had a significant benefit in terms of surgical approach from the use of salvage chemotherapy, the majority of them (73.3%) were still deemed as inoperable or candidates for an extensive surgical procedure. One could argue that these patients may have received an unnecessary treatment which, in addition to the abovementioned risk of tumour progression, could also be associated with increased toxicities and possibly detriment of quality of life. The design of our study does not allow us to estimate the benefit (if any) of salvage chemotherapy in this group of patients. However, we have shown that administering systemic chemotherapy after chemoradiotherapy led to some incremental tumour response (as indicated by a number of imagingbased parameters) which, regardless of the type of surgical resection performed (i.e., TME or beyond-TME), may have ultimately translated into improved outcome. Also, it should be noted that, in view of the high-risk features of their tumours, these patients would be very likely to be proposed the same treatment after surgery, a setting where the efficacy of chemotherapy is yet to be demonstrated and the risk of toxicity and low compliance appears significantly higher compared with pre-operative chemotherapy [38, 39] .
Our analysis has a number of limitations in addition to the small sample size and the retrospective design. The definition of tumour resectability in this study was based on MR imaging that has been previously reported to be as effective as pathology at predicting the likelihood of local recurrence, disease-free survival and overall survival [40] . Furthermore mrTRG has also been validated as a method of predicting response to treatment [21, 41] . However, especially when non high-resolution techniques are employed and MERCURY-defined criteria are not used, MRI is less specific in the assessment of parameters such as involvement of the mesorectal fascia after administration of neoadjuvant chemoradiotherapy [42, 43] . Nevertheless, it is unlikely that this may have led to an excess of patients who were considered to be inoperable or candidates for extensive surgical approaches after standard chemoradiotherapy and became suitable for TME after chemotherapy. In our study 4 out of 26 patients (15%) who were deemed to be candidates for a beyond-TME surgical approach after salvage chemotherapy ultimately underwent TME. While imaging cannot confidently rule out residual microscopic foci of cancer within the dense fibrotic tissue threatening/involving the mesorectal fascia, the discrepancy between type of surgery that was recommended after completion of salvage chemotherapy and that which was actually carried out is more likely to reflect the willingness of some surgeons to cut through fibrotic tissue to allow a sphincter-preserving surgery rather than an overall poor accuracy of MRI as such. This also reflects the learning curve of our MDT in relation to the management of patients with locally advanced tumours who are likely candidates for a beyond-TME surgical approach. Moreover, the relatively long interval between MRI assessment after salvage chemotherapy and surgery may have accounted for at least some of the observed discrepancies. The contention that the results of our study are not significantly biased by the decision to rely on MRI for the assessment of tumour resectability and definition of surgical plan is supported by the fact that 2 out of 10 patients who underwent TME following chemotherapy were truly inoperable as reported by the treating surgeon during exploratory surgery after completion of chemoradiotherapy.
Another potential limitation is the median time interval from completion of chemoradiotherapy to tumour assessment which in our study was lower (i.e., 4.4 weeks) compared with what is now considered as the optimal standard by international guidelines and consensus statements on LARC beyond TME planes (i.e., 6-8 weeks) [6, 14, 44] . Therefore, it cannot be excluded that some of the downstaging/downsizing effects which have been attributed to salvage systemic chemotherapy may actually be secondary to delayed radiotherapy-induced tumour regression [45, 46] . However, it is worth noting that in 2 cases tumour resectability according to the TME principles was achieved only after approximately 6 months of systemic chemotherapy, this being continued beyond the first MRI after 3 months of treatment showed that an extensive surgery was still required. This mitigates against a significant impact of possible confounding factors on the study results and further support a true "rescue effect" of salvage chemotherapy in this setting. Especially in this group of locally advanced tumours with no/minimal signs of tumour regression soon after completion of chemoradiotherapy, it is very unlikely that a substantial, chemoradiotherapy-induced, delayed tumour regression may have occurred and led to a change in surgical approach. Indeed, studies suggest that the highest benefit from neoadjuvant chemoradiotherapy (in terms of tumour downstaging, pathological complete response or radical resection) is observed from 8 to 11 weeks after completion of treatment [46, 47] . Delaying surgery beyond this timeframe may actually increase the risk of positive resection margins possibly as a result of tumour re-growth [47] .
Main strengths of our analysis are the adoption of a well-defined, largely homogeneous management pathway for LARC patients for the duration of the study and the collection of prospectively annotated recommendations from institutional MDT meetings which were regularly attended by a highly experienced team of clinicians including specialised gastrointestinal radiologists and colorectal surgeons. Also, although the overall study period spanned over approximately 15 years, the vast majority of patients were treated within the last 5 years, this reinforcing the contention that our findings are generalisable to the current clinical practice. This strategy is being tested in a prospective multicentre trial (TRIGGER) in which patients are randomised to an experimental arm of sequential systemic chemotherapy or deferral of surgery based on mrTRG after chemoradiotherapy (NCT02704520) [48] .
In conclusion, our retrospective analysis suggests that systemic chemotherapy could be a useful salvage strategy for high-risk LARC patients who are still inoperable or require extensive surgical procedures after standard chemoradiotherapy. While administering chemotherapy in this setting may already be a relatively common practice in some centres, this has been largely empirical and not supported by any evidence. Herein we provide for the first time a valuable source of information on the potential of salvage chemotherapy that can be used in the decision-making process whenever the prospect of an exenterative-type resection or palliative treatment is envisaged after failure of standard neoadjuvant therapy. Prospective studies are certainly required to confirm our data and possibly assess the role of systemic chemotherapy in this setting against alternative therapeutic options. No study has ever addressed the role of systemic chemotherapy as salvage treatment option in this setting.
To consider the lack of high-quality evidence for the management of LARC patients who remain inoperable or candidate for extensive surgical procedures following neoadjuvant chemoradiotherapy.
To obtain valuable information on the potential of systemic chemotherapy as salvage treatment after failure of standard neoadjuvant chemoradiotherapy.
To recognise chemoradiotherapy refractory LARC as an area of unmet need and prioritise research in this setting. who underwent macroscopically radical resection (i.e., R0 or R1) or were managed with a "watch and wait" approach (n=25)
